» Articles » PMID: 32634494

Comparison of Two Biomarker Only Algorithms for Early Risk Stratification in Patients with Suspected Acute Coronary Syndrome

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2020 Jul 8
PMID 32634494
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We developed a biomarker algorithm encompassing the clinical chemistry score (CCS; which includes the combination of a random glucose concentration, an estimated glomerular filtration rate and high-sensitivity cardiac troponin; hs-cTn) with the Ortho Clinical Diagnostics hs-cTnI assay (CCS-serial) and compared it to the cutoffs derived from Ortho Clinical Diagnostics 0/1 h (h) algorithm for 7-day myocardial infarction (MI) or cardiovascular (CV)-death.

Methods: The study cohort was an emergency department (ED) population (n = 906) with symptoms suggestive of acute coronary syndrome (ACS) who had two Ortho hs-cTnI results approximately 3 h apart. Diagnostic parameters (sensitivity/specificity/negative predictive value; NPV/positive predictive value; PPV) were derived for the CCS-serial and the 0/1 h algorithm for 7-day MI/CV-death. A safety analysis was performed for patients in the rule-out arms of the algorithms for 30-day MI/death.

Results: The CCS-serial algorithm yielded 100% sensitivity/NPV (32% low-risk) and 95.7% specificity/65% PPV (11% high-risk). The 0/1 h algorithm-cutoffs yielded sensitivity/NPV/specificity/PPV of 97.8%/99.4%/91.3%/50%, which classified 38% of patients as low-risk and 16% of patients as high-risk. Four patients (1.2%) in the 0/1 h algorithm-cutoff rule-out arm had a 30-day MI/death outcome as compared to zero patients in the CCS-serial rule-out arm (p = 0.06).

Conclusion: Both the CCS-serial and 0/1 h algorithm cutoffs yield high NPVs with a similar proportion of patients identified as low-risk. These data may be useful for sites who are unable to collect samples at 0/1 h in the emergency department.

Citing Articles

The Clinical Validation of a Common Analytical Change Criteria for Cardiac Troponin for Ruling in an Acute Cardiovascular Outcome in Patients Presenting with Ischemic Chest Pain Symptoms.

Kavsak P, Sharif S, Globe I, Ainsworth C, Ma J, McQueen M J Cardiovasc Dev Dis. 2023; 10(8).

PMID: 37623348 PMC: 10455380. DOI: 10.3390/jcdd10080335.


Serial high-sensitivity cardiac troponin testing for the diagnosis of myocardial infarction: a scoping review.

Ohtake H, Terasawa T, Zhelev Z, Iwata M, Rogers M, Peters J BMJ Open. 2022; 12(11):e066429.

PMID: 36414302 PMC: 9685223. DOI: 10.1136/bmjopen-2022-066429.


Diagnostic Performance of Serial High-Sensitivity Cardiac Troponin Measurements in the Emergency Setting.

Kavsak P, Hewitt M, Mondoux S, Cerasuolo J, Ma J, Clayton N J Cardiovasc Dev Dis. 2021; 8(8).

PMID: 34436239 PMC: 8397128. DOI: 10.3390/jcdd8080097.


Disagreement between Cardiac Troponin Tests Yielding a Higher Incidence of Myocardial Injury in the Emergency Setting.

Kavsak P, Mondoux S, Martin J, Hewitt M, Clark L, Caruso N J Cardiovasc Dev Dis. 2021; 8(3).

PMID: 33806960 PMC: 8004643. DOI: 10.3390/jcdd8030031.


Acute Phase Response and Non-Reproducible Elevated Concentrations with a High-Sensitivity Cardiac Troponin I Assay.

Kavsak P, Clark L, Martin J, Mark C, Pare G, Mondoux S J Clin Med. 2021; 10(5).

PMID: 33801415 PMC: 7958626. DOI: 10.3390/jcm10051014.